Prevention and regression of non-alcoholic steatohepatitis (NASH) in a rat model by metabosartan, telmisartan

  • Authors:
    • Hironori Nakagami
    • Mariana Kiomy Osako
    • Futoshi Nakagami
    • Takashi Shimosato
    • Noriko Minobe
    • Toshinori Moritani
    • Munehisa Shimamura
    • Takashi Miyake
    • Hideo Shimizu
    • Yasushi Takeya
    • Ryuichi Morishita
  • View Affiliations

  • Published online on: October 1, 2010     https://doi.org/10.3892/ijmm_00000488
  • Pages: 477-481
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The favorable metabolic effects of telmisartan have been attributed to its angiotensin II receptor blockade and action as a partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ. We previously reported that administration of telmisartan markedly inhibited lipid accumulation in the liver in mice fed a high-fat diet. In the present study, we further examined the protective effect of telmisartan in a non-alcoholic steatohepatitis (NASH) model induced by feeding Wistar rats an L-methionine- and choline-deficient (MCA) diet. In the first experiment, rats were fed an MCA diet for 8 weeks with or without telmisartan (3 mg/kg/day). Liver fibrosis was observed by Masson trichrome staining, and co-treatment was shown to attenuate liver fibrosis. In the second experiment, Wistar rats were fed an MCA diet for 20 weeks, and telmisartan (3 mg/kg/day) was administered during weeks 0-20 as a preventive model or weeks 8-20 as a therapeutic model. As a result, telmisartan administration in both models significantly attenuated liver fibrosis and an increase in serum AST. Of importance, the HGF concentration in the liver was significantly increased in the telmisartan-treated group. Overall, telmisartan showed a potential action to improve NASH induced by an MCA diet, possibly due to increased HGF production through partial agonist of PPAR-γ. These favorable characteristics of telmisartan as a partial agonist of PPAR-γ may provide a benefit in the treatment of metabolic syndrome beyond its blood pressure-lowering effect.

Related Articles

Journal Cover

October 2010
Volume 26 Issue 4

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Nakagami H, Kiomy Osako M, Nakagami F, Shimosato T, Minobe N, Moritani T, Shimamura M, Miyake T, Shimizu H, Takeya Y, Takeya Y, et al: Prevention and regression of non-alcoholic steatohepatitis (NASH) in a rat model by metabosartan, telmisartan . Int J Mol Med 26: 477-481, 2010.
APA
Nakagami, H., Kiomy Osako, M., Nakagami, F., Shimosato, T., Minobe, N., Moritani, T. ... Morishita, R. (2010). Prevention and regression of non-alcoholic steatohepatitis (NASH) in a rat model by metabosartan, telmisartan . International Journal of Molecular Medicine, 26, 477-481. https://doi.org/10.3892/ijmm_00000488
MLA
Nakagami, H., Kiomy Osako, M., Nakagami, F., Shimosato, T., Minobe, N., Moritani, T., Shimamura, M., Miyake, T., Shimizu, H., Takeya, Y., Morishita, R."Prevention and regression of non-alcoholic steatohepatitis (NASH) in a rat model by metabosartan, telmisartan ". International Journal of Molecular Medicine 26.4 (2010): 477-481.
Chicago
Nakagami, H., Kiomy Osako, M., Nakagami, F., Shimosato, T., Minobe, N., Moritani, T., Shimamura, M., Miyake, T., Shimizu, H., Takeya, Y., Morishita, R."Prevention and regression of non-alcoholic steatohepatitis (NASH) in a rat model by metabosartan, telmisartan ". International Journal of Molecular Medicine 26, no. 4 (2010): 477-481. https://doi.org/10.3892/ijmm_00000488